Dr. Davis on Immunotherapy in HER2-Positive Gastric/GEJ Cancer
September 4th 2019S. Lindsey Davis, MD, an assistant professor of medicine and gastrointestinal medical oncologist at the University of Colorado Cancer Center, discusses an investigational immunotherapy combination being explored in patients with HER2-positive gastric and gastroesophageal junction (GEJ) cancer.
Read More
Dr. Davis on the Role of Ramucirumab in Gastric/GEJ Cancer
August 20th 2019S. Lindsey Davis, MD, an assistant professor of medicine and gastrointestinal medical oncologist at the University of Colorado Cancer Center, discusses the role of ramucirumab (Cyramza) in the treatment of patients with gastric/gastroesophageal junction (GEJ) adenocarcinoma.
Read More
Dr. Davis on Caveats of the KEYNOTE-062 Trial Findings in Gastric/GEJ Cancer
June 25th 2019S. Lindsey Davis, MD, an assistant professor of medicine and gastrointestinal medical oncologist at the University of Colorado Cancer Center, discusses caveats of the phase III KEYNOTE-062 trial findings in gastric and gastroesophageal junction (GEJ) cancer.
Read More